Drugmakers see huge potential in antibody-drug conjugates market

10/22/2013 | Chemical & Engineering News

Drugmakers and contract drug manufacturers are stepping up their investments in antibody-drug conjugates prompted by the huge sales potential of this new class of cancer drugs. Roche Holding's breast cancer drug Kadcyla and Seattle Genetics' lymphoma treatment Adcetris are the only ADCs available on the market, and others are largely in early development, but the market is predicted to expand to $9 billion by 2023. Roche and MedImmune are among those working on their ADC pipelines. Contract manufacturers such as Carbogen Amcis and Piramal Healthcare are investing in their ADC production capabilities.

View Full Article in:

Chemical & Engineering News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN